MSCL Satellos Bioscience Inc.
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.…
Industry Peers
BiotechnologyKey Statistics
About Satellos Bioscience (TSE: MSCL)
›
Satellos Bioscience (TSE: MSCL) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 18 employees.
The shares were at 8.240 CAD on 20 November 2026, down 7.2% over 52 weeks. Its 52-week range is 7.560 CAD to 18.98 CAD: the price is 56.6% below the high and 9.0% above the low.
Its market capitalisation is 174.82M CAD.
Satellos Bioscience reports return on equity of -89.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 61.84M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 17.67 CAD is 114.4% above the current price. The next earnings report is expected on 25 March 2027.